KRYS Krystal Biotech Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KRYS

Price (delayed)

$161.025

Market cap

$4.56B

P/E Ratio

402.56

Dividend/share

N/A

EPS

$0.4

Enterprise value

$4.21B

Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.

Highlights
The net income has soared by 137% from the previous quarter and by 108% YoY
The EPS has soared by 129% from the previous quarter and by 107% YoY
The company's quick ratio rose by 32% YoY but it fell by 16% QoQ
The company's gross margin fell by 3.6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.krystalbio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of KRYS
Market
Shares outstanding
28.29M
Market cap
$4.56B
Enterprise value
$4.21B
Valuations
Price to earnings (P/E)
402.56
Price to book (P/B)
5.83
Price to sales (P/S)
86.24
EV/EBIT
326.09
EV/EBITDA
234.9
EV/Sales
82.95
Earnings
Revenue
$50.7M
EBIT
$12.9M
EBITDA
$17.9M
Free cash flow
-$603,000
Per share
EPS
$0.4
Free cash flow per share
-$0.02
Book value per share
$27.61
Revenue per share
$1.87
TBVPS
$30.14
Balance sheet
Total assets
$818.36M
Total liabilities
$39.71M
Debt
$8.09M
Equity
$778.64M
Working capital
$554.82M
Liquidity
Debt to equity
0.01
Current ratio
17.76
Quick ratio
17.35
Net debt/EBITDA
-19.56
Margins
EBITDA margin
35.3%
Gross margin
93.9%
Net margin
21.6%
Operating margin
-216.4%
Efficiency
Return on assets
1.5%
Return on equity
1.6%
Return on invested capital
3.2%
Return on capital employed
1.6%
Return on sales
25.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KRYS stock price

How has the Krystal Biotech stock price performed over time
Intraday
0.5%
1 week
2.64%
1 month
-9.47%
1 year
91.9%
YTD
29.8%
QTD
-9.5%

Financial performance

How have Krystal Biotech's revenue and profit performed over time
Revenue
$50.7M
Gross profit
$47.61M
Operating income
-$109.73M
Net income
$10.93M
Gross margin
93.9%
Net margin
21.6%
The net income has soared by 137% from the previous quarter and by 108% YoY
The net margin has soared by 106% from the previous quarter
The operating margin has soared by 87% from the previous quarter
The operating income has grown by 26% from the previous quarter and by 24% YoY

Growth

What is Krystal Biotech's growth rate over time

Valuation

What is Krystal Biotech stock price valuation
P/E
402.56
P/B
5.83
P/S
86.24
EV/EBIT
326.09
EV/EBITDA
234.9
EV/Sales
82.95
The EPS has soared by 129% from the previous quarter and by 107% YoY
KRYS's P/B is 61% above its 5-year quarterly average of 3.6 and 32% above its last 4 quarters average of 4.4
Krystal Biotech's equity has increased by 49% YoY and by 3% QoQ

Efficiency

How efficient is Krystal Biotech business performance
Krystal Biotech's return on invested capital has surged by 141% QoQ and by 108% YoY
Krystal Biotech's ROA has soared by 133% from the previous quarter and by 106% YoY
The ROE has soared by 133% from the previous quarter and by 106% YoY
The ROS has soared by 107% from the previous quarter

Dividends

What is KRYS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KRYS.

Financial health

How did Krystal Biotech financials performed over time
The company's total assets rose by 47% YoY and by 3.5% QoQ
The current ratio is up by 34% year-on-year but it has declined by 16% since the previous quarter
The debt is 99% less than the equity
The debt to equity has plunged by 50% YoY
Krystal Biotech's equity has increased by 49% YoY and by 3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.